Almirall shares soar after impressive six months

22 July 2024

Spanish dermatology specialist Almirall (BME: ALM) was trading 4% higher at the end of Monday’s trading day in Barcelona.

Almirall earlier announced its financial results from the first half of 2024, delivering strong sales growth in the second quarter of the year, which was mainly driven by the dermatology business in Europe.

Total net sales for the six-month period increased by 6.7% to a total of 497.2 million euros ($541.2 million), while earnings before interest, taxes, depreciation and amortization (EBITDA) were 104.5 million, a rise of 3.2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical